Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02832089

Enrollment

Registered

2016-07-14

Start date

2000-12-31

Completion date

2002-03-31

Last updated

2016-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, rate reduction

Brief summary

Oral carvedilol administered in escalating doses in patients with atrial fibrillation among patients with AF with fast ventricular rate.

Detailed description

Patients with AF with FVR of any etiology were evaluated and given escalating doses of oral carvedilol in doses - 3.125mg OD, then 3.125 bid, then 6.25mg bid, then 12.5mg bid. The ECG was recorded regularly and analysed for rate reduction or control.

Interventions

DRUGoral carvedilol

oral carvedilol in escalating doses for reducing ventricular rate in AF patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* AF with fast ventricular rate

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
reduction in ventricular rate in AF patients	24 hours	reduction in ventricular rate in patients with AF and fast ventricular rate.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026